The results of studies large enough to permit a subtype analysis have shown that pCRs tend to concentrate in patients with HER2 overexpressing or triple negative tumours.12–14 Moreover, lobular carcinoma has been associated with poor response to chemotherapy.19 Here, ERBB2 is linked to breast lobular carcinoma.